Friend virus is a complex of replication-competent Friend murine leukemia virus (F-MuLV) and a replication-defective Friend spleen focus-forming virus (F-SFFV) (Ben-David and Bernstein, 1991) . The Friend helper Murine Leukemia Virus (F-MuLV) induces a variety of hematological disorders of lymphoid, myeloblastic and erythroid nature, depending on the mouse genetic background and the age of virus inoculation (Shibuya and Mak, 1982) . In FMuLV-induced erythroleukemia, the spleen and liver are massively invaded by infected erythroid progenitor cells. The leukemic progression involves dierent gene modi®cations such as proviral integration events and gene rearrangements or mutations. Proviral integration occurs in the Fli-1 locus in 75% of the infected mice (Ben-David et al., 1990; Sels et al., 1992) . The insertional activation of the Fli-1 gene appears to be the ®rst genetic detectable event associated with FMuLV-induced primary erythroleukemias. However, rearrangements of the Pim-1 and the c-myc genes are also observed and often associated with rearrangements of the p53 gene in the same tumor (Dreyfus et al., 1990) . In contrast to Friend complex-induced erythroleukemias, no Spi-1 rearrangement is observed in F-MuLV-induced erythroid tumors (Moreau-Gachelin et al., 1988) .
In addition, rearrangements of the Epo gene resulting in constitutive Epo expression seem to be of a relatively common occurrence in transplantable erythroid tumors induced by the helper F-MuLV. Three independent studies reported the production and secretion of Epo in F-MuLV-induced erythroleukemias, leading to the hypothesis that Epo was involved in an autocrine process associated with enhanced tumorigenicity in vivo and growth factorindependence in vitro (Tambourin et al., 1983; Hankins et al., 1986; Howard et al., 1996) . In a previous study, we reported that two out of seven FMuLV-induced erythroleukemias in ICFW mice produced Epo (Lacombe et al., 1987) whereas Howard found an Epo-production in 12 out of 15 Balb/c-derived erythroleukemia cell lines (Howard et al., 1996) . Two groups detected rearrangements of the Epo gene in erythroleukemia cell lines (Howard et al., 1996; McDonald et al., 1987; Beru et al., 1989) . Activation of the Epo gene was found to be independent of retroviral insertional mutagenesis, but the molecular mechanisms leading to production of Epo were not clearly understood.
IW32 cell line has been established in vitro from a transplantable murine erythroleukemia induced by FMuLV (Tambourin et al., 1983) . IW32 cells express Epo receptors (Lacombe et al., 1987) . In addition, these cells secrete Epo constitutively and proliferate without addition of any growth factor (Choppin et al., 1984 (Choppin et al., , 1985 . The mechanism responsible for the transcriptional activation of the Epo gene was studied and it was shown that IW32 cells contained both a normal Epo gene and a rearranged locus. Both the normal and rearranged Epo genes have been cloned and their upstream regions sequenced. The rearrangement breakpoint was found to be located 1.17 kb upstream from the Epo initiating codon (McDonald et al., 1987) . A DNAse I hypersensitive site was located further 5', approximately 1.9 kb upstream from the breakpoint. The presence of this DNAse I hypersensitive site localizes the Epo gene in an open chromatin conformation and could therefore allow its transcrip-tion. Furthermore, a transcriptional unit in opposite orientation to the Epo gene was located in the vicinity of this DNAse I hypersensitive site (Figure 1 ). The authors hypothesized that this transcriptionally active gene was brought closely enough to the Epo gene to allow the activation of the abnormal Epo allele in IW32 cells (Beru et al., 1989) . In this paper, we describe the molecular mechanism responsible for Epo expression in the IW32 cell line.
We cloned the full-length cDNA of the murine Gprotein b2 subunit from a 16-day-murine embryo cDNA library in lEXlox vector. In order to fully characterize this cDNA, we compared its sequence to GenBank by fasta program. Surprisingly, we found that, in addition to homology to the coding sequence of the G-protein b2 subunit, the 5' end of this cDNA contained a stretch of 104 bp that perfectly matched a sequence located inside the rearranged IW32 locus previously cloned by Beru et al. (1989) (locus MUSERPB in GenBank data). This 104 bp sequence corresponded to the 5' non coding sequence of the Gprotein b2 subunit cDNA ( Figure 2 ). Because this sequence was not available in the GenBank, the unknown locus located 5' to the rearranged Epo gene could not be ascribed to the G-protein b2 subunit gene. This 104 bp sequence is localized 44 bp 3' to the DNAse I hypersensitive site identi®ed by Beru et al. (1989) , which allows to localize a functional promoter of this gene (see Figure 4A ). A perfect splice donor site (GTACC) is located 3' to this 104 bp sequence. Thus, the G-protein b2 subunit sequence of 104 bp corresponds to the ®rst non coding exon of this gene. Moreover, the G-protein b2 subunit gene is in the same orientation as the Epo gene, suggesting that the transcriptional activation of this Epo allele could be under the control of the G-protein b2 subunit promoter.
Epo and G-protein b2 subunit loci (Gnb2) have been mapped on the same chromosome. In the mouse genome, these loci are positioned on chromosome 5 (Figure 3) (Lacombe et al., 1988; Kozak et al., 1996) . In human, Lovett et al. (1991) using a method for direct isolation of cDNAs encoded by large genomic regions, have positioned the Gnb2 gene within 30 ± 70 kb of the Epo gene on chromosome 7. Consequently, in IW32 cells, the Epo gene rearrangement results from a small chromosomal deletion joining the Figure 1 Schematic structure of the rearranged Epo locus (Beru et al., 1989) . The arrow indicates the breakpoint of this rearrangement. The unknown gene transcribed in opposite direction of the Epo gene is indicated. HS localizes the DNase I hypersensitive site In order to study the consequence of the fusion of the G-protein b2 subunit gene with the Epo gene, we performed a reverse transcription of IW32 mRNA using a speci®c oligonucleotide (Epo2: 5'-TGGCC-TCTAAGATGTACCTCT-3') localized in the second exon of the Epo gene. A PCR was then performed using two oligonucleotides: Epo2 described above and one oligonucleotide speci®c for the G-protein b2 subunit exon 1 (Gb2: 5'-CCATCCGCGTCGCC-GCCGCT-3') ( Figure 4B ). The resulting PCR product was cloned and sequenced. As seen on Figure 4 , the sequence of the G-protein b2 subunit exon 1 is fused to a sequence corresponding to the 3' region of the Epo exon 1. The presence within Epo exon 1 of a consensus splice site (TCCAG) located 5' to the Epo initiation site of translation allows the formation of a fusion mRNA and the conservation of the normal Epo coding sequence ( Figure 4A ). Thus, in the IW32 cell line, the Epo gene of the rearranged abnormal allele is under the control of the G-protein g2 subunit promoter, and the expressed mRNA results from the fusion of the non coding exon 1 of the G-protein b2 subunit gene with a truncated Epo exon 1 gene. The careful examination of the primary sequence located 5' to the cloned G-protein b2 subunit cDNA indicates that it contains all the characteristics of an ubiquitous promoter: absence of TATA and CAAT boxes, presence of GC rich sequences (71% GC in the 110 bp located 5' to the cDNA sequences) and presence of a SP1 consensus sequence (750). A DNAse I hypersensitive site (744), revealing an open chromatin conformation, also favors the presence of a promoter or an enhancer. Furthermore, an unknown transcriptional unit in opposite orientation has been localized 1 kb 5' to the cloned G-protein b2 subunit cDNA (Beru et al., 1989 and Figure 4A ). Most likely, the G-protein b2 subunit promoter should be localized 3' to this unidenti®ed gene.
We never observed, either in the PCR products (only one ampli®ed band with an oligonucleotide localized in Epo exon 2) or in the PCR sequences (5 clones), a splicing of the noncoding exon 1 of G-protein b2 subunit gene with the second exon of the Epo gene. This indicates that the splicing site found inside the ®rst exon of the Epo gene is functional. This latter observation could suggest the putative existence of another exon located 5' to the published Epo gene structure. Many studies focused on the mechanisms regulating Epo gene expression have shown that the cis-acting sequences involved in hepatic and renal expression of Epo were dierent (Semenza et al., 1990 (Semenza et al., , 1991 Maxwell et al., 1993) ; moreover, Epo expression has also been detected in the brain (Masuda et al., 1994; Digicaylioglu et al., 1995) . Speci®c expression in dierent tissues could involve alternative promoters of the same gene, as it was described for the porphobilinogen deaminase (ChreÂ tien et al., 1988) , pyruvate kinase (Noguchi et al., 1987) , (Max-Audit et al., 1993) and choline acetyl transferase genes (Chireux et al., 1995) . RNase protection assays have been performed to determine the initiation sites of Epo gene transcription. Dierent transcriptional initiation sites have been identi®ed in liver and kidney (Semenza et al., 1990) , but there is no experimental evidence to con®rm the hypothesis of an alternative exon located 5' of the published Epo gene exon 1.
The relationship between autocrine stimulation by Epo and malignant transformation of erythroleukemic cells is still unclear. It seems that autocrine stimulation and additional events such as gene rearrangements or mutations are necessary to lead to a leukemic process. Indeed, in previous studies, overexpression of the Epo gene in normal murine hematopoietic cells through a retroviral construct, resulted in a proliferative syndrome and not to malignant transformation (Hoatlin et al., 1990; Villeval et al., 1992) . A similar polycythemic disorder has been reported for mice transgenic for the human Epo gene (Semenza et al., 1989) . In contrast, in human erythroleukemias, autocrine stimulation by Epo could in several cases explain the autonomous growth of erythroid leukemic cells. Reduced autonomous cell growth could be obtained by Epo-neutralizing antibodies or only by Epo antisense oligonucleotides, indicating that this process could be an extracellular or intracellular autocrine stimulation (Mitjavila et al., 1991) . In F-MuLV-induced erythroleukemias, transformation of erythroid cells seemed to be frequently associated with synthesis and secretion of Epo. Some authors found an inhibition of the growth of these Epoproducing cells by anti-Epo antibodies (Howard et al., 1996) , whereas others obtained a suppression of proliferation of erythroleukemic cells by using antisense oligomers corresponding to the Epo or Epo receptor 5' coding sequences (Stage-Marroquin et al., 1996) . This latter result favored an internal autocrine Epo stimulation of the cells. One of the intracellular events following binding of Epo to its surface receptors is the activation of the STAT5 transcription factor (Pallard et al., 1995; Wakao et al., 1995) . Moreover, STAT5 activation seems to correlate with Epo-induced cellular proliferation (Damen et al., 1995; Gobert et al., 1996; . The Epo receptors are probably activated in IW32 cells since, in contrast to other F-MuLV-induced erythroleukemia cell lines that do not produce Epo, the STAT5 transcription factor is constitutively activated in these cells (data not shown). Thus, activation of Epo receptors due to autocrine Epo stimulation could provide a growth advantage to IW32 leukemic cells and contribute to the oncogenic progression.
The activation of the Epo receptor also plays an important role in Friend-derived erythroleukemias. Indeed, it has been shown that the gp55 envelope product encoded by SFFVp directly bound to and activated the Epo receptor. Coexpression of gp55 and Epo receptor conferred-Epo independence to infected hematopoietic cell lines and was suggested to be responsible for the preleukemic erythroblastosis in vivo (Li et al., 1990 ). An activating point mutation in the extracellular domain of the Epo receptor was also shown to confer growth factor-independence (Yoshimura et al., 1990) ; subsequent experiments showed that adult mice developed polycythemia and leukemia upon infection with a viral construct containing this mutated Epo receptor (Longmore and Lodish, 1991) .
Finally, it is interesting to note that, in murine virusinduced erythroleukemia, Epo receptor activation could result from two distinct mechanisms: in FMuLV diseases, autocrine Epo stimulation could trigger the activation of its cognate receptor, whereas in SFFVp-induced disorders, this activation is due to the association of the gp55 envelope product with the Epo receptor. The two retroviruses may have dierent target cells; one hypothesis could be that F-MuLV transforms erythroid progenitors only when they are able to produce Epo in a transient autocrine manner (Hankins et al., 1986) . Indeed, a transient autocrine role for Epo during bone marrow erythropoiesis has been proposed and could account for this phenomenon (Hermine et al., 1991) .
We identi®ed the molecular mechanism leading to the abnormal expression of Epo in one F-MuLVinduced erythroleukemia cell line. It would be of interest to examine whether identical molecular features are involved in other erythroleukemic human and murine Epo-producing cells.
